These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 12967804)

  • 21. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
    Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
    Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ; Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection.
    Oliveira AD; Höfling-Lima AL; Belfort R; Gayoso Mde F; Francisco W
    Arq Bras Oftalmol; 2007; 70(2):286-9. PubMed ID: 17589701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
    Ko WC; Chiang SR; Lee HC; Tang HJ; Wang YY; Chuang YC
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2217-22. PubMed ID: 12821471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
    Yamada M; Hatou S; Yoshida J
    Eye Contact Lens; 2008 Mar; 34(2):109-12. PubMed ID: 18327047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimum inhibitory concentrations of standard and novel antimicrobials for isolates from bacterial keratitis.
    Sueke H; Kaye S; Neal T; Murphy C; Hall A; Whittaker D; Tuft S; Parry C
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2519-24. PubMed ID: 20019362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
    Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones.
    Graves A; Henry M; O'Brien TP; Hwang DG; Van Buskirk A; Trousdale MD
    Cornea; 2001 Apr; 20(3):301-5. PubMed ID: 11322420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
    Barry AL; Fuchs PC; Brown SD
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
    Epstein SP; Bottone EJ; Asbell PA
    Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G; Alfonso EC; Miller D
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
    Heinemann B; Wisplinghoff H; Edmond M; Seifert H
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2211-3. PubMed ID: 10898706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
    Johnson AP; Warner M; Livermore DM
    Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antibiotic susceptibility patterns of bacteria isolated from keratitis and intraocular infections at Fundación Oftalmológica de Santander (FOSCAL), Floridablanca, Colombia].
    Galvis V; Tello A; Guerra A; Acuña MF; Villarreal D
    Biomedica; 2014 Apr; 34 Suppl 1():23-33. PubMed ID: 24968033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.